Day One

• FasTarg is an ML/AI-assisted bioinformatics approach to identify novel TCE targets for solid tumour indications
• iOmx’s integrated discovery and development platform enables the generation ofhighly potent TCE compounds
• Show-casing a TCE program with potent tumour cell killing activity and a favourable safety profile

• Unlocking a new target class: The “Dark Genome” is a rich, untapped source of tumour-specific antigens, overcoming the limitations of many conventional TCE targets (poor tumour specificity, low prevalence, low intra-tumoural homogeneity)
• End-to-end platform solution: Enara Bio has built integrated discovery (EDAPT) and engineering (EnTiCE) platforms to identify Dark Antigens® and generate optimised TCEs capable of effective engagement at physiological antigen levels
• First-in-class validation with DARKFOX/ENA101: We have identified a highly tumour-specific, broadly expressed antigen and targeted it with a potent, selective TCE showing strong preclinical efficacy, safety, and translational potential

This session is your opportunity to get face-to-face with many of the brightest minds working on TCE development, and establish meaningful business and scientific relationships to pursue for the rest of the conference

• What defines a ‘clean’ target in practice, and how should we balance prevalence, selectivity, and heterogeneity risks?
• How can emerging technologies like proteomics, spatial biology, and AI improve prediction of protein expression, localisation, and off-tumour toxicity risk?
• How can the field move beyond a limited pool of validated targets while generating robust preclinical data to de-risk novel target investment?

• Novel approach to T-cell engagers against intracellular targets: T-Cypher uses TCR-based bispecifics to target intracellular cancer antigens that conventional therapies can’t reach
• Proprietary AI discovery platform: An internally-developed engine rapidly identifies and optimises high-affinity TCRs with exceptional safety profiles
• Two lead programs moving toward the clinic: Advanced pipeline with near-term IND filings and clear clinical development timelines

• T-cell engagers (TCE) have long held promise for the treatment of solid tumours
• However, most TCEs are limited by on target off tumour activity and associated safety liabilities
• By leveraging the AbiLeap™ platform, Ability Biotherapeutics has developed pH sensing TCEs, active in the low pH microenvironment of the tumour but not in the periphery, providing an avenue for developing precision targeted TCE therapeutics

• LabGenius Therapeutics has pioneered the development of EVA™, an ML-driven, closed-loop antibody discovery engine. EVA™ generates large volumes of biologically rich experimental data, which are used to train computational models. These models are used to co-optimise molecules across multiple therapeutic parameters, including potency, efficacy, selectivity and developability
• By integrating high-throughput experimentation and computational learning in this way, EVA™ identifies novel, high-performing antibody molecules, often with nonintuitive designs
• The company’s lead programme, LGTX-101, is a selectivity-enhanced Nectin-4 x CD3 T-cell engager featuring a novel 3+1 molecular architecture. In preclinical studies, LGTX-101 has demonstrated robust tumour-killing activity with minimal activity against Nectin-4–expressing healthy cells

This is an informal session to help you connect with your peers in a relaxed atmosphere and forge new and beneficial relationships. With an audience of cell engager experts eager to hear the latest innovations and positive movement, ou will have the opportunity to display a poster presenting your own work.

• MP0632 redefines precision T-cell engagement through logic-gated design to address limited immunotherapy efficacy in high unmet need solid tumours
• Dual targeting of MSLN and EpCAM enables selective activation in dual-positive tumour cells with no signs of peripheral T-cell activation, reducing off-tumour effects and supporting expansion to other co-expressing indications
• CD2 co-stimulation sustains T-cell function and potency, driving durable, localised responses with an improved therapeutic window and favourable safety profile

• Harness computational protein design and modelling for next-gen TCE platform
• Lead program focused on “AND”-gated design that enhances tumour selectivity while minimising on-target off-tumour toxicities
• Platform modularity provides an opportunity to generate multiple therapeutic TCEs for various solid tumours

• The efficacy of T-cell engagers in solid tumors is often limited by systemic toxicities, including on-target/off-tumor effects
• Our next-generation approach utilizes a conditionally-activated platform designed to restrict T-cell engagement to the tumor microenvironment via tumor-associated proteases
• This strategy minimises off-tumor activity and systemic immune activation while maintaining robust anti-tumor efficacy, thereby significantly widening the therapeutic window for treatment